La Jolla Pharmaceutical – Technology Overview

Deirdre Gillespie Leads Advisory Efforts at Invigor Consulting

Deirdre Gillespie possesses nearly three decades of experience as a business leader in the pharmaceutical and biotechnology industries. In addition to her many leadership roles that include serving as the executive chairperson of IRAD Oncology, Inc., Deirdre Gillespie lends her expertise to emerging companies as the CEO of Invigor Consulting.

Invigor Consulting advises pharmaceutical and biotechnology firms in both North America and Europe, providing operational and strategic support throughout all phases of business development. Gillespie and the company assist clients in developing business plans, assembling effective leadership teams, and forming advisory groups. Additionally, Invigor Consulting helps businesses to navigate financing options that include forming partnerships and garnering fundraising support.

In overseeing the company’s consulting activities, Gillespie also draws on her experience in all four phases of clinical development to guide clients through the process. Experienced in several therapeutic areas, she specializes in oncology, lupus, female sexual interest/arousal disorders, and infectious diseases. Her extensive experience in both business management and clinical development allows her to advise clients in a variety of matters, including clinical planning and protocol design. Invigor Consulting also facilitates interactions with opinion leaders and contract research organizations. In addition, the company provides guidance on meetings with the Food and Drug Administration.


Apricus Biosciences – Products in Development

Deirdre Gillespie, president and CEO of La Jolla Pharmaceutical Company, also serves on the board of Apricus Biosciences, Inc. Apricus develops products to improve the sexual health and well-being of men and women alike. As a board member, Deirdre Gillespie works to make sure Apricus is on the fastest route to achieving its mission of developing quality products. Below are profiles of Apricus’ two primary products in development, Vitaros and Femprox.

Vitaros is novel in the sense that it treats erectile dysfunction with a topical, as opposed to internal, solution. The cream is applied directly to the member and works to increase blood flow immediately. It contains alprostadil, a known agent in aiding in erectile dysfunction. Vitaros is currently approved in Canada and Europe, and is expected to be launched into the market in 2014.

Femprox, the female analogue to Vitaros, treats female sexual dysfunction. Also like Vitaros, Femprox is a cream applied locally that works to create female arousal on an as-needed basis. Femprox also contains alprostadil. Though Femprox is not currently approved anywhere, Apricus is working to make it the first approved drug of its kind.

Royal College of Physicians Takes on Teaching in South Sudan

Dr. Deirdre Gillespie, who heads La Jolla Pharmaceutical Company as president and CEO, belongs to the Royal College of Physicians. The organization is devoted to improving the health and professionalism of the medical community and its patients. As a member, Dr. Deirdre Gillespie stays up to date with the group’s latest news.

A new project was recently announced by the Royal College of Physicians to teach local citizens of the Republic of South Sudan better health practices. Volunteers, in tandem with clinical faculty at the Juba Teaching Hospital in the Republic’s capital city, will instruct doctors new to the practice of medicine in essential medical skills. Due in part to devastating civil war, local doctors with a senior level of medical experience are few and far between, and this project will help to fill the experience gap.

The project will begin in February 2014 and last three years. Over 100 new doctors are expected to attain instruction. Other Royal Medical Colleges have indicated that they may follow suit with their own programs if this one proves successful.

Lupus – A Basic Overview

The chief executive officer and president of La Jolla Pharmaceutical Company, Inc., from 2006 to 2012, Dr. Deirdre Gillespie has worked in health care since beginning her career as a physician in the United Kingdom in the 1980s. During her tenure at La Jolla Pharmaceutical Company, Dr. Deirdre Gillespie oversaw the largest systemic lupus erythematosis study ever conducted at the time.

Lupus is an autoimmune disease characterized by inflammation, swelling, and damage to many of the body’s systems, including the lungs, skin, joints, kidneys, blood, and heart. Lupus makes the immune system incapable of differentiating between healthy tissue and viruses and bacteria and sends antibodies to attack healthy tissue. The disease effects between 1.2 and 1.4 million Americans and has no definitive known cause. The most distinctive lupus symptom is a rash that spreads across the face, although the rash does not occur in all instances. Lupus has no cure, but treatments can be very effective and lessen the effect of symptoms.

Equity Financing – Helping Companies Grow

Over the course of her nearly three-decade career as a physician, researcher, and executive in the life sciences, Dr. Deirdre Gillespie has worked for businesses like Sandoz Pharma and Vical, Inc. Most recently, Dr. Deirdre Gillespie functioned as the chief executive officer and president for La Jolla Pharmaceutical Company, Inc. In addition to her leadership in guiding the development of pharmaceutical treatments, she has become adept at the equity financing process.

Equity financing refers to raising capital for a business by selling shares of ownership rather than borrowing capital from a lending institution. This type of financing allows businesses to receive the capital without having to repay it or take on debt. However, equity investors share in any profits and have the right to be consulted regarding any business decisions.

Usually, startup businesses have several rounds of equity financing from investors and venture capitalists to grow the company without acquiring costly debt. Debt financing, conversely, allows the business owner to make his or her own choices but may saddle the business with enough debt to hinder positive cash flow.